Close Menu

J&J

This article originally ran on May 15 and has been updated to include additional comments from GlaxoSmithKline.
GlaxoSmithKline said today that it has entered an agreement to purchase chemical proteomics firm Cellzome for £61 million ($99 million).

By Adam Bonislawski
University of North Carolina researchers have developed a chemical proteomics approach to measure global kinase activity and used it to investigate drug resistance in triple-negative breast cancer.

Belgian protein biomarker firm Pronota has raised €3.7 million ($4.9 million) a Series C financing round that it will use to complete protein biomarker validation studies for its pre-eclampsia, ovarian cancer, sepsis, and cardio-renal programs.

Title: Gene Silencing
Patent Number: 8,097,710
Filed: March 22, 2004
Lead Inventor: David Baulcombe, Plant Bioscience

Foundation Medicine has struck a deal with Johnson & Johnson Pharmaceutical Research and Development to use Foundation's targeted sequencing cancer test to identify potential biomarkers that could be of interest for the pharmaceutical company's clinical oncology programs.

NEW YORK (GenomeWeb News) – Foundation Medicine today said that it will partner with Johnson & Johnson Pharmaceutical Research and Development in a biomarker identification collaboration.

FDA Commissioner Margaret Hamburg has hired Steven Spielberg, director of the Center for Personalized Medicine and Therapeutic Innovation at Children’s Mercy Hospital in Kansas City, for the newly created position of deputy commissioner for medical products and tobacco.

The deal marks the first pharma alliance for Evotec since it acquired Kinaxo in mid-April in a deal worth up to $23 million.

IP Update: Jun 24, 2011

Premium

Recent Patents in Bioinformatics, May — June 2011

Three UK-funded projects, led by Life Technologies, Source BioScience, and Oxford Gene Technologies, aim to develop tests based on several platforms, including the Ion Torrent PGM and Illumina HiSeq.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.